Immobilized PAR monoclonal antibody in the wells of a 96-well plate captures cellular PAR and PAR attached to proteins. Incubation with a polyclonal PAR detecting antibody, followed by addition of a goat anti-rabbit IgG-HRP secondary and a chemiluminescent HRP substrate yields relative light units (RLU) that directly correlates with the amount of cellular PAR.
- Pre-coated 96 well capture antibody plates
- High signal to noise ratio
- Detection sensitivity of 2 pg/ml of PAR
- Broad linear dynamic range to 1,000 pg/ml
- Reduced inter-assay variability
- Validated assay that measures drug action on PARP in both in vivo and in vitro settings
- 96 test size
- Quantitation of PAR in peripheral blood mononuclear cells, tissue culture cells, and tumor lysates from different tissues, organs and xenografts.
- Monitoring the efficacy of PARP inhibitors on PAR formation in vivo.
- Verifying observations of enhanced cancer cell cytotoxicity arising from PARP inhibitor/anticancer drug combination therapy.
- Facilitating development of PARP and PARG targeted therapeutics.
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
Lee, J., Hays, J.L., Annunziata, C.M., Noonan, A.M., Minasian, L., Zujewski, J.A., Yu, M., Gordon, N., Ji, J., Sissung, T.M., Figg, W.D., Azad, N.,Wood, B.J., Doroshow, J. and Kohn, E.C.
J Natl Cancer Inst, May 2014; 106: dju089.
Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations
Kinders, R., Ferry-Galow, K., Wang, L., Srivastava, A.K., Ji, J. and Parchment, R.E.
Clin. Cancer Res., May 2014; 20: 2578 – 2586.
Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition
Julie K. Horton, Donna F. Stefanick, Rajendra Prasad, Natalie R. Gassman, Padmini S. Kedar, and Samuel H. Wilson
Mol. Cancer Res., Aug 2014; 12: 1128 – 1139.
“Efficacy of Carboplatin Alone and in Combination with
ABT888 in Intracranial Murine Models of BRCA-Mutated
and BRCA–Wild-Type Triple-Negative Breast Cancer”
“Olga Karginova, Marni B. Siegel, Amanda E.D. Van Swearingen, Allison M. Deal,
Barbara Adamo, Maria J. Sambade, Soha Bazyar, Nana Nikolaishvili-Feinberg, Ryan
Bash, Sara O’Neal, Katie Sandison, Joel S. Parker, Charlene Santos, David Darr,
William Zamboni, Yueh Z. Lee, C. Ryan Miller, and Carey K. Anders”
Mol. Cancer Ther., Apr 2015; 14: 920 – 930.
Global Transcriptome Analysis Reveals That Poly(ADP-Ribose) Polymerase 1 Regulates Gene Expression through EZH2
Kayla A. Martin, Matteo Cesaroni, Michael F. Denny, Lena N. Lupey, and Italo Tempera
Mol. Cell. Biol., Dec 2015; 35: 3934 – 3944.
“Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and
Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA
Mutation–Associated Breast Cancer”
“Eve T. Rodler, Brenda F. Kurland, Melissa Griffin, Julie R. Gralow, Peggy Porter, Rosa F. Yeh, Vijayakrishna
K. Gadi, Jamie Guenthoer, Jan H. Beumer, Larissa Korde, Sandra Strychor, Brian F. Kiesel, Hannah M.
Linden, John A. Thompson, Elizabeth Swisher, Xiaoyu Chai, Stacie Shepherd, Vincent Giranda, and
Jennifer M. Specht”
Clin. Cancer Res., Jun 2016; 22: 2855 – 2864
Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1
Kayla A. Martin, Lena N. Lupey, and Italo Tempera
J. Virol., Oct 2016; 90: 8520 – 8530